Advice

in the absence of a submission from the holder of the marketing authorisation:

ranibizumab (Lucentis®) is not recommended for use within NHSScotland.

Indication under review: treatment of proliferative diabetic retinopathy in adults.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice610KB (PDF)

Download

Medicine details

Medicine name:
ranibizumab (Lucentis)
SMC ID:
SMC2270
Indication:

Treatment of proliferative diabetic retinopathy in adults.

Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
Submission type
Non submission
Date advice published
10 February 2020